Payment overview · 2025
General Payments
$234.42
14 reported records · 9 companies
Healthcare provider profile · identity verified
Christopher W Teague, MD
Allopathic & Osteopathic Physicians|Family Medicine · HILLSBORO, TX · NPI 1821064486
Verified facts
What the public records show
CMS Open Payments records show Christopher W Teague, MD received $234.42 in general payments during 2025 across 14 reported records.
PFIZER INC. accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 170 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $55.78 | 23.8% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.12 | 14.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $33.69 | 14.4% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.45 | 13.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.36 | 7.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.03 | 6.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.96 | 6.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.76 | 6.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.27 | 6.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $234.42 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.78 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.78 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.78 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.12 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.12 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $33.69 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.45 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 170 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 64 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
71 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
170 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 697 | 138 |
| Amlodipine Besylate | Amlodipine Besylate | 602 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 537 | 86 |
| Lisinopril | Lisinopril | 466 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 458 | 88 |
| Gabapentin | Gabapentin | 449 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 442 | 86 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 379 | 44 |
| Losartan Potassium | Losartan Potassium | 359 | 71 |
| Alprazolam | Alprazolam | 308 | 42 |
| Furosemide | Furosemide | 300 | 65 |
| Trazodone Hcl | Trazodone Hcl | 285 | 57 |
| Tramadol Hcl | Tramadol Hcl | 261 | 55 |
| Meloxicam | Meloxicam | 259 | 55 |
| Carvedilol | Carvedilol | 258 | 44 |
| Metformin Hcl Er | Metformin Hcl | 246 | 48 |
| Potassium Chloride | Potassium Chloride | 245 | 43 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 236 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 229 | 46 |
| Omeprazole | Omeprazole | 223 | 42 |
| Montelukast Sodium | Montelukast Sodium | 219 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 216 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 215 | 52 |
| Simvastatin | Simvastatin | 210 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 209 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 195 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 183 | 29 |
| Metformin Hcl | Metformin Hcl | 183 | 37 |
| Eliquis | Apixaban | 170 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 170 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 156 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 152 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 152 | 21 |
| Glimepiride | Glimepiride | 150 | 31 |
| Spironolactone | Spironolactone | 150 | 29 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 146 | 31 |
| Pregabalin | Pregabalin | 140 | 27 |
| Sertraline Hcl | Sertraline Hcl | 135 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 118 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 116 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 17 |
| Methylprednisolone | Methylprednisolone | 110 | 83 |
| Torsemide | Torsemide | 110 | 28 |
| Allopurinol | Allopurinol | 109 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 107 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 106 | 22 |
| Celecoxib | Celecoxib | 106 | 16 |
| Ozempic | Semaglutide | 105 | 17 |
| Mirtazapine | Mirtazapine | 101 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 100 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 98 | 15 |
| Prednisone | Prednisone | 97 | 49 |
| Buspirone Hcl | Buspirone Hcl | 93 | 14 |
| Famotidine | Famotidine | 92 | 16 |
| Januvia | Sitagliptin Phosphate | 91 | 16 |
| Baclofen | Baclofen | 88 | 13 |
| Donepezil Hcl | Donepezil Hcl | 86 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 18 |
| Memantine Hcl | Memantine Hcl | 82 | suppressed |
| Azithromycin | Azithromycin | 79 | 67 |
| Levetiracetam | Levetiracetam | 73 | suppressed |
| Methocarbamol | Methocarbamol | 73 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 26 |
| Amoxicillin | Amoxicillin | 71 | 41 |
| Linzess | Linaclotide | 71 | 16 |
| Colchicine | Colchicine | 68 | 12 |
| Bupropion Xl | Bupropion Hcl | 66 | 14 |
| Mounjaro | Tirzepatide | 64 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 63 | 13 |
| Ezetimibe | Ezetimibe | 63 | 20 |
| Farxiga | Dapagliflozin Propanediol | 63 | 12 |
| Aripiprazole | Aripiprazole | 62 | 12 |
| Atenolol | Atenolol | 61 | 11 |
| Diazepam | Diazepam | 60 | suppressed |
| Dutasteride | Dutasteride | 58 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 42 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 11 |
| Lorazepam | Lorazepam | 57 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 52 | 12 |
| Nystatin | Nystatin | 52 | 20 |
| Promethazine Hcl | Promethazine Hcl | 49 | suppressed |
| Etodolac | Etodolac | 48 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 13 |
| Clonidine Hcl | Clonidine Hcl | 46 | suppressed |
| Glipizide Er | Glipizide | 46 | 11 |
| Warfarin Sodium | Warfarin Sodium | 46 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | suppressed |
| Glipizide | Glipizide | 43 | suppressed |
| Temazepam | Temazepam | 43 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 40 | suppressed |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Indomethacin | Indomethacin | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Risperidone | Risperidone | 37 | suppressed |
| Naproxen | Naproxen | 36 | 14 |
| Midodrine Hcl | Midodrine Hcl | 35 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Mupirocin | Mupirocin | 34 | 17 |
| Chlorthalidone | Chlorthalidone | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 26 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 16 |
| Lansoprazole | Lansoprazole | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 13 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 16 |
| Metolazone | Metolazone | 26 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Minoxidil | Minoxidil | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Glyburide | Glyburide | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 19 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 19 | suppressed |
| Latanoprost | Latanoprost | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Nystop | Nystatin | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 12 |
| Metronidazole | Metronidazole | 16 | 13 |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Ertapenem | Ertapenem Sodium | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Nucynta Er | Tapentadol Hcl | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Ethosuximide | Ethosuximide | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | 11 |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $234.42 · 14 records | PFIZER INC. | ABRYSVO, CAPVAXIVE, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, GARDASIL 9, M-M-R II, MOUNJARO, NURTEC ODT, PREVNAR 20, REXULTI, ROTATEQ, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VAXELIS, VRAYLAR, Veozah, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error